AbbVie Inc. (4AB.DE) XETRA

196.60

+2.6(+1.34%)

Updated at October 17 05:35PM

Currency In EUR

AbbVie Inc.

Address

1 North Waukegan Road

North Chicago, IL 60064-6400

United States of America

Phone

847 932 7900

Sector

Healthcare

Industry

Drug Manufacturers - General

Employees

55000

First IPO Date

May 17, 2016

Key Executives

NameTitlePayYear Born
Mr. Robert A. Michael CPAChief Executive Officer & Director5.97M1970
Mr. Scott T. ReentsExecutive Vice President & Chief Financial Officer3.42M1968
Mr. Timothy J. RichmondExecutive Vice President & Chief Human Resources Officer3.44M1966
Dr. Azita Saleki-Gerhardt Ph.D.Executive Vice President & Chief Operating Officer3.63M1963
Mr. Jeffrey Ryan StewartExecutive Vice President & Chief Commercial Officer4.47M1969
Mr. Richard A. GonzalezExecutive Chairman7.21M1954
Mr. Perry C. SiatisExecutive Vice President, General Counsel & Secretary01976
Dr. Roopal Thakkar M.D.Executive Vice President of Research and Development & Chief Scientific Officer01973
Mr. Wulff-Erik von BorckeSenior Vice President & President of Oncology0N/A
Ms. Elizabeth SheaSenior Vice President of Investor Relations0N/A

Description

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.